Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | RAPGEF3 | O95398 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19223773 | 0.86 | KDR (0.56) | KDRGRM4RAPGEF4TRPV1LMNA | |
| SCHEMBL19089350 | 0.79 | AR (0.45) | KDRGRM4RAPGEF4RAPGEF3TRPV1 | |
| SCHEMBL20656067 | 0.76 | RAPGEF3 (0.41) | KDRGRM4RAPGEF4RAPGEF3TRPV1 | |
| SCHEMBL11201462 | 0.76 | APEX1 (0.67) | KDRTRPV1PDK1GSTO1 | |
| SCHEMBL9725601 | 0.76 | KDR (0.43) | KDRGRM4RAPGEF4RAPGEF3TRPV1 | |
| SCHEMBL11525237 | 0.76 | KDR (0.43) | KDRGRM4RAPGEF4RAPGEF3TRPV1 | |
| SCHEMBL11414045 | 0.76 | KDR (0.47) | KDRGRM4RAPGEF4RAPGEF3TRPV1 | |
| SCHEMBL20655719 | 0.75 | AR (0.49) | KDRGRM4RAPGEF4RAPGEF3TRPV1 | |
| SCHEMBL10389130 | 0.74 | RAPGEF3 (0.42) | KDRGRM4RAPGEF4RAPGEF3TRPV1 | |
| SCHEMBL28875490 | 0.72 | KDR (0.57) | KDRTRPV1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, NUTF2 | KDR 1558/4885GRM4 4543/4885RAPGEF4 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.